The Patented Medicine Prices Review Board (PMPRB) will remove the United States and Switzerland from the list of countries to which it compares Canadian pharmaceutical costs to determine how much companies can charge consumers for drugs. It will add Japan, Spain, Norway, Belgium and the Netherlands to existing comparators France, Germany and Italy. The PMPRB will also begin using the market price—what consumers actually pay on average, after rebates—instead of the sticker price in its calculations of what drug companies can charge for medications. The changes will take effect on July 1, 2020. (The Logic)
In-depth, agenda-setting reporting
Great journalism delivered straight to your inbox.
Digital car-auction platform E Automotive files for TSX IPO
Union takes umbrage after Stellantis cuts Windsor plant to single shift, citing chip shortage
Canadian miner Noront now favours Wyloo Metals in bidding war with BHP
Competition Bureau investigating Google’s YouTube ad practices
Best business newsletter in Canada
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership to The Logic Council
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our newsroom team and special guests.